Indication
Post-Polycythemic Myelofibrosis Phase
4 clinical trials
5 products
1 drug
Clinical trial
A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AMLStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
AzacitidineProduct
PevonedistatProduct
VenetoclaxClinical trial
A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With MyelofibrosisStatus: Recruiting, Estimated PCD: 2024-12-31
Drug
ElotuzumabClinical trial
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)Status: Completed, Estimated PCD: 2022-05-19
Product
Smac Mimetic LCL161Clinical trial
Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative NeoplasmStatus: Recruiting, Estimated PCD: 2025-04-30
Product
Ruxolitinib